Table 1.
Clinical characteristics of the breast cancer patients in this study.
| HR+/HER2– (n = 410) No. (%) | |
|---|---|
| Median age (min–max) (years) | 47.3 (25.2–80.5) |
| Age (years) | |
| <50 | 241 (58.8%) |
| ≥50 | 169 (41.2%) |
| Tumor size (cm) | |
| ≤ 2 | 183 (44.6%) |
| 2-5 | 204 (49.8%) |
| >5 | 23 (5.6%) |
| Lymph node status | |
| Negative | 203 (49.5%) |
| Positive | 207 (50.5%) |
| pN | |
| 0 | 203 (49.5%) |
| 1 | 112 (27.3%) |
| 2 | 51 (12.4%) |
| 3 | 44 (10.7%) |
| Pathologic stage | |
| I | 113 (27.6%) |
| II | 197 (48.0%) |
| III | 100 (24.4%) |
| Histologic grade | |
| 1 | 77 (18.8%) |
| 2 | 199 (48.5%) |
| 3 | 123 (30%) |
| Unknown | 11 (2.7%) |
| Nuclear grade | |
| 1 | 60 (14.6%) |
| 2 | 256 (62.4%) |
| 3 | 81 (19.8%) |
| Unknown | 13 (3.2%) |
| Hormone therapy | |
| No | 21 (5.1%) |
| Yes | 379 (92.4%) |
| Unknown | 10 (2.4%) |
| Chemotherapy | |
| No | 68 (16.6%) |
| Yes | 342 (83.4%) |
| Unknown | 0 (0.0%) |
| Radiotherapy | |
| No | 162 (39.5%) |
| Yes | 247 (60.2%) |
| Unknown | 1 (0.2%) |
| NPI | |
| 1 | 113 (27.6%) |
| 2 | 113 (27.6%) |
| 3 | 113 (27.6%) |
| 4 | 58 (14.1%) |
| Unknown | 13 (3.2%) |
HR, hormone receptor; HER2, human epidermal growth factor receptor 2; TNBC, triple-negative breast cancer; pN, pathologic nodal status; NPI, Nottingham prognostic index.